These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30607538)

  • 21. Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis.
    Al-Khatib SM; Fonarow GC; Joglar JA; Inoue LYT; Mark DB; Lee KL; Kadish A; Bardy G; Sanders GD
    JAMA Cardiol; 2017 Jun; 2(6):685-688. PubMed ID: 28355432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials.
    Wolff G; Lin Y; Karathanos A; Brockmeyer M; Wolters S; Nowak B; Fürnkranz A; Makimoto H; Kelm M; Schulze V
    Clin Res Cardiol; 2017 Jul; 106(7):501-513. PubMed ID: 28213711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale and study protocol for the BRITISH randomized trial (Using cardiovascular magnetic resonance identified scar as the benchmark risk indication tool for implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy and severe systolic heart failure).
    Flett A; Cebula A; Nicholas Z; Adam R; Ewings S; Prasad S; Cleland JG; Eminton Z; Curzen N
    Am Heart J; 2023 Dec; 266():149-158. PubMed ID: 37777041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).
    Kutyifa V; Moss AJ; Klein H; Biton Y; McNitt S; MacKecknie B; Zareba W; Goldenberg I
    Circulation; 2015 Oct; 132(17):1613-9. PubMed ID: 26316618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac device therapy in patients with left ventricular dysfunction and heart failure: 'real-world' data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital).
    Boriani G; Berti E; Belotti LM; Biffi M; De Palma R; Malavasi VL; Bottoni N; Rossi L; De Maria E; Mantovan R; Zardini M; Casali E; Marconi M; Bandini A; Tomasi C; Boggian G; Barbato G; Toselli T; Zennaro M; Sassone B;
    Eur J Heart Fail; 2016 Jun; 18(6):693-702. PubMed ID: 27060289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implantable Cardioverter Defibrillator for the Primary Prevention of Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy.
    Cavalcanti R; Aboul-Hosn N; Morales G; Abdel-Latif A
    Angiology; 2018 Apr; 69(4):297-302. PubMed ID: 28554215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temporal Trends Over a Decade of Defibrillator Therapy for Primary Prevention in Community Practice.
    Boveda S; Narayanan K; Jacob S; Providencia R; Algalarrondo V; Bouzeman A; Beganton F; Defaye P; Perier MC; Sadoul N; Piot O; Klug D; Gras D; Fauchier L; Bordachar P; Babuty D; Deharo JC; Leclercq C; Marijon E;
    J Cardiovasc Electrophysiol; 2017 Jun; 28(6):666-673. PubMed ID: 28251724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary prevention of sudden cardiac death by implantable cardioverter-defibrillator therapy in Chinese patients with heart failure: a single-center experience.
    Chen TB; Cheng KA; Gao P; Cheng ZW; Fan JB; Jiang XC; Fang Q
    Chin Med J (Engl); 2010 Apr; 123(7):848-51. PubMed ID: 20497676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death.
    Das M
    Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):181-95. PubMed ID: 19210214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in underlying cardiac substrate among S-ICD recipients and its impact on long-term device-related outcomes: Real-world insights from the iSUSI registry.
    Gasperetti A; Schiavone M; Milstein J; Compagnucci P; Vogler J; Laredo M; Breitenstein A; Gulletta S; Martinek M; Casella M; Kaiser L; Santini L; Rovaris G; Curnis A; Biffi M; Kuschyk J; Di Biase L; Tilz R; Tondo C; Forleo GB;
    Heart Rhythm; 2024 Apr; 21(4):410-418. PubMed ID: 38246594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized study of cardiac resynchronization therapy defibrillator versus dual-chamber implantable cardioverter-defibrillator in ischemic cardiomyopathy with narrow QRS: the NARROW-CRT study.
    Muto C; Solimene F; Gallo P; Nastasi M; La Rosa C; Calvanese R; Iengo R; Canciello M; Sangiuolo R; Diemberger I; Ciardiello C; Tuccillo B
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):538-45. PubMed ID: 23592833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis.
    Barra S; Duehmke R; Providencia R; Marijon E; Boveda S; Virdee M; Heck P; Fynn S; Begley D; Grace A; Agarwal S
    Europace; 2018 Jan; 20(1):89-96. PubMed ID: 28031276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy.
    Verma A; Sarak B; Kaplan AJ; Oosthuizen R; Beardsall M; Wulffhart Z; Higenbottam J; Khaykin Y
    Pacing Clin Electrophysiol; 2010 Mar; 33(3):320-9. PubMed ID: 19796352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator.
    Daimee UA; Vermilye K; Moss AJ; Goldenberg I; Klein HU; McNitt S; Zareba W; Kutyifa V
    Heart Rhythm; 2018 Sep; 15(9):1379-1386. PubMed ID: 29678779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a systematic review and meta-analysis of prospective randomized clinical trials.
    Romero J; Chaudhary R; Garg J; Lupercio F; Shah N; Gupta R; Nazir T; Bozorgnia B; Natale A; Di Biase L
    J Interv Card Electrophysiol; 2017 Sep; 49(3):263-270. PubMed ID: 28674918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimated Glomerular Filtration Rate and Implantable Cardioverter-Defibrillator in Nonischemic Systolic Heart Failure: Extended Follow-Up of DANISH.
    Doi SN; Thune JJ; Nielsen JC; Haarbo J; Videbæk L; Yafasova A; Bruun NE; Gustafsson F; Eiskjær H; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Køber L; Butt JH
    J Am Heart Assoc; 2024 Feb; 13(3):e031977. PubMed ID: 38293926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators.
    Peterson PN; Greenlee RT; Go AS; Magid DJ; Cassidy-Bushrow A; Garcia-Montilla R; Glenn KA; Gurwitz JH; Hammill SC; Hayes J; Kadish A; Reynolds K; Sharma P; Smith DH; Varosy PD; Vidaillet H; Zeng CX; Normand ST; Masoudi FA
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.